Introduction {#s1}
============

Elderly patients with severe aortic valve stenosis and high operative risk can be treated by transcatheter aortic valve replacement (TAVR) with equivalent outcome to surgical aortic valve replacement (SAVR).^[@JEV055C1]--[@JEV055C4]^ Aortic valve stenosis is the most common valve disease in elderly patients, and TAVR is increasingly being performed.^[@JEV055C5]^ According to TAVR guidelines, pre-procedural planning requires a contrast-computed tomography (CT) from thorax to iliofemoral vessels.^[@JEV055C6]--[@JEV055C8]^ Due to the higher prevalence of tumours in elderly patients,^[@JEV055C9]^ more potential malignant incidental findings (pmIFs) are expected in CTs of these patients.

If a radiologic pmIF appears, the clinician must interpret its significance and the consequence for further treatment. On the one hand, potential malignancies could be diagnosed and treated, but conversely unnecessary diagnostic workup of possibly benign findings could increase costs,^[@JEV055C10],[@JEV055C11]^ threaten patients by invasive diagnostics, and lead to increased anxiety.^[@JEV055C12],[@JEV055C13]^ Furthermore, a pmIF with unclear significance could influence the decision of the heart team since TAVR guidelines do not recommend intervention in patients with an estimated survival below 1 year.^[@JEV055C7]^ The diagnostic workup triggered by the pmIF could delay intervention on the aortic valve and thus could raise mortality in patients with severe aortic valve stenosis,^[@JEV055C1],[@JEV055C5],[@JEV055C14]^ and the burden of symptoms of aortic valve stenosis limits quality of life of patients when an intervention with a fast recovery could be performed.

It is unknown whether the presence of suspicious pmIF with an estimated patient survival of \>1 year correlates with mortality in elderly patients planned for aortic valve replacement. Therefore, the purpose of this systematic retrospective observational study is to evaluate the prevalence and relevance of potentially malignant unsuspected pmIF with respect to treatment decision, time to treatment, and 2-year survival.

Methods {#s2}
=======

Study design {#s2a}
------------

The study is a retrospective, single-centre observational study in 414 participants who underwent CT for evaluation of TAVR between October 2010 and December 2012 at the University Heart Center Freiburg. Only patients with severe aortic valve stenosis were included for further analyses. Participants were retrospectively screened for pmIF, which were suspicious for malignancy as assessed by a senior radiologist. An interdisciplinary heart team consisting of cardiologist, heart surgeon, and radiologist made the decision for conservative, best medical therapy only (drug therapy), or invasive treatment, i.e. SAVR or TAVR. The follow-up period ended at January 2014. All participants gave informed consent. The ethical committee of the University of Freiburg approved the study design, and the study complies with the Declaration of Helsinki.

Pre-procedural dual-source CT scanner {#s2b}
-------------------------------------

All examinations were performed on a first-generation dual-source CT scanner (DSCT, Somatom Definition, Siemens Healthcare) using the following scan parameters: 330 ms gantry rotation time, detector collimation 0.6 mm, and tube voltage of 120 kV. A scout view of thorax and abdomen was obtained to plan data acquisitions. After a single contrast medium injection, combined ECG-assisted scanning of the thorax and the upper chest (including 2--3 cm of the arteria carotis), and non-ECG-assisted scanning of the abdomen were performed. The total amount of contrast agent (Imeron 350^®^, Bracco, Konstanz, Germany) and flow rate were adapted to body weight: patients weighing \<70 kg received 110 mL of contrast agent at 4 mL/s and those weighing 70 kg or more received 130 mL at 4.5 mL/s, followed by a saline bolus chaser of 50 mL administered at an equal flow rate. The reference tube current time product was twice as high for the lower part of the chest as for the upper part, with the boundary ∼2 cm below the carina. Attenuation-based tube current modulation (CareDOSE, Siemens Healthcare) and prospective ECG-triggered tube current modulation^[@JEV055C12]^ were used for radiation dose reduction, the latter with a pulsing window between 30 and 80% of the R--R cycle and tube current lowered to 20% of the maximum outside the pulsing window. The scanner was operated in the single-source mode for the abdomen. A preceding delay of 4 s was necessary to change the scanning mode. Patients were instructed to sustain their breath-hold if possible or to continue shallow breathing.

Follow-up {#s2c}
---------

Follow-up period was from October 2010 until January 2014. Participants with a pmIF in the initial DSCT were followed up for 2 years and either contacted by telephone or presented in the outpatient clinic.

Classification of incidental findings {#s2d}
-------------------------------------

To distinguish highly suspicious from rather benign findings, the pmIFs were divided into two groups as the clinician and heart team must do to interpret the radiologic finding: 'severe' or 'non-severe'. The findings of the 'severe' group reflected a potential limitation of the patients' life expectancy, which has to be taken into account during the decision-making process by the heart team. These findings are clinically suspicious for malignant growth. The following characteristics defined a 'severe' pmIF: metastasis with primary tumour, infiltrating or progressive tumour with or without inhomogeneous contrast uptake, bulky lymph nodes, multiple metastases, or osteolysis. Non-severe findings are clinically less likely for malignant growth. The following characteristics defined a 'non-severe' pmIF, described as rather cystic or other disease, organ hyperplasia (e.g. prostate), small nodules with or without recommendation for a follow-up, inhomogeneous contrast uptaking organ, and single lymph nodes.

Statistical analysis {#s2e}
--------------------

Quantitative continuous variables are described with means ± standard deviation and quantitative discrete variables with relative frequencies. Baseline characteristics were compared using the Students *t*-test, the Mann--Whitney *U* test, and the *χ*^2^ test when appropriate. To identify the incidental findings relevance for treatment decision, a multivariable logistic regression model was fitted including the logistic EuroScore I, age, as a classification of the clinical significance of the incidental finding. Variable selection took place according to clinical relevance as well as according to previous works on the relevance of patient-specific variables for Heart-team decision-making.^[@JEV055C15]^ For missing variables, multiple imputation was applied. Two-year cumulative survival rates were estimated by means of the Kaplan--Meier method. Differences between groups were determined using the Log-rank test. All analyses were performed using Stata 12 (StataCorp, College Station, TX, USA).

Results {#s3}
=======

A total of 414 subjects, who underwent screening for TAVR with DSCT at the University Heart Center Freiburg between October 2010 and December 2012, were eligible. Severe aortic valve stenosis (mean valve area 0.7 ± 0.2 cm^2^) was diagnosed in 374 patients who participated in the study (*Figure [1](#JEV055F1){ref-type="fig"}*). The mean age of the study population was 79.8 ± 8.9 years and 55.3% were women. Unexpected pmIFs were detected in 70 (18.7%) patients (Table [1](#JEV055TB1){ref-type="table"}). Patients with pmIF were significantly older (mean age 82 vs. 79 years), other baseline parameters did not differ including kidney function, incidence of smoking, or diabetes. Table 1Baseline characteristics were collected during the TAVR screeningAllNo incidental findingIncidental finding*P*-value*n* = 374*n* = 304*n* = 70MeanSDMeanSDMeanSDFemale55.3%55.3%55.7%0.945Age (years)79.83±8.9279.26±9.3182.33±6.450.009Body weight (kg)70.90±15.7570.71±15.9271.74±15.020.622NYHA Class2.63±0.712.62±0.712.66±0.720.529Pulmonary hypertension21.4%21.4%21.4%0.993Ejection fraction %48.92±10.6948.75±10.9949.67±9.350.515Aortic valve area (cm^2^)0.71±0.210.70±0.190.74±0.280.218Log EuroScore I18.7%±13.3%18.9%±13.7%18.1%±11.5%0.645Arterial hypertension82.9%81.9%87.1%0.294Hyperlidaemia53.5%52.0%60.0%0.225Smoker (current)21.4%21.4%21.4%0.665Diabetes27.8%28.0%27.1%0.891Chronic lung disease15.8%16.1%14.3%0.704Stadium chronic renal failure (KDOQI CKF^[@JEV055C16]^)2.80±0.862.80±0.872.81±0.800.945Dialysis2.9%3.0%2.9%0.963Liver disease4.0%4.6%1.4%0.221[^1] Figure 1The flow diagram shows eligible participants. pmIFs were classified into 'severe' and 'non-severe'. The interdisciplinary heart team made the decision for TAVR, SAVR, or drug therapy only.

Most pmIFs were found within the thorax (in 26 participants), 19 were within the abdomen, and 21 retroperitoneum or mamma. Ten patients with a history of malignant disease were incidentally diagnosed as having progressive or relapsing disease. Finally, four participants had pmIF in other regions such as thyroid or multiple osteolysis (Table [2](#JEV055TB2){ref-type="table"}). Table 2Potential malignant incidental findings were classified in 'severe' or 'non-severe' and are assigned to different regionsRegion*n* severe pmIF*n* not-severe pmIFThorax\
*n* = 26**422**2 pulmonary nodule with progressive/infiltrating growth1 pulmonary nodule with typical malignant lymph nodes1 multiple pulmonary nodules (\>1 cm)10 single pulmonary nodules5 mediastinal (lymph-) node4 pleural thickening2 multiple pulmonary nodules (\<1 cm)1 thyroid augmentationAbdomen\
*n* = 19**613**2 liver mass with inhomogeneous contrast uptake1 progressive known hepatocellular cancer1 pancreas mass with progressive/infiltrating growth and metastasis1 new/progressive pulmonary nodules1 unilateral adrenal gland augmentation with suspicious contrast uptake5 organ augmentation (5 adrenal gland)2 inhomogeneous contrast uptake (1 liver, 1 pancreas)1 likely hepatic hemangioma1 small mass in biliary tract1 cystic mass (1 pancreas)1 unspecific lymph nodesRetroperitoneum or Mamma\
*n* = 21**156**7 renal mass with/without metastasis3 new/progressive pulmonary nodules by known abdominal tumour2 prostate augmentation infiltrating or progressive tumour ±inhomogeneous contrast uptake2 mamma tumour progressive/infiltrating growth and metastasis1 new osteolysis by known prostate cancer2 ovarian cyst/adnex cyst2 prostate augmentation2 not significant pulmonary nodules (\<1 cm) by known cancerOther\
*n* = 4**31**3 multiple osteolysis1 thyroid cystRelapse/progress all regions\
*n* = 10**82**6 primary tumour within retroperitoneum or Mamma: ○ 3 new/progressive pulmonary nodules○ 2 irregular Mamma or new metastasis○ 1 osteolysis2 primary tumour within abdomen: ○ 1 progressive hepatocellular cancer○ 1 new/progressive pulmonary nodules2 primary tumour within retroperitoneum ○ 1 new pleural thickening○ 1 single pulmonary nodule[^2]

The heart team has to assess these findings and decide which patient has a life expectancy of over 2 years and should be assigned to aortic valve repair. Notably, 40% of the pmIFs were severe and therefore highly suspicious for malignancies, but only 21% (*n* = 15) were finally confirmed.

The average NYHA score of 2.6 indicated the symptomatic nature, apparent suffering, and need for intervention in this cohort. From 70 patients with pmIF, 56 underwent transcatheter or surgical treatment (45 TAVR, 11 SAVR) and 14 drug therapy (*Figure [2](#JEV055F2){ref-type="fig"}*). Figure 2Time to treatment was retrospectively analysed in patients with or without pmIF. Results are presented in days after decision-making to the intervention. Decision of the interdisciplinary heart team is stated below.

As expected, age and EuroScore I had an impact on the decision to intervene in comparison to conservative drug therapy only, indicating that patients of high age and/or with high EuroScore I values were more likely to be assigned drug therapy only. The presence of any non-severe pmIF did not influence the decision to propose invasive treatment, but patients with an IF judged as 'severe' were much less likely to receive an intervention (OR 0.23; *P* = 0.019) (Table [3](#JEV055TB3){ref-type="table"}). Table 3The decision by the interdisciplinary heart team to intervene was retrospectively analysed with a multivariable logistic regression modelDecision to interveneOdds ratio*P*-valueEuroScore I0.95\>0.001Age0.950.067Non-severe incidental finding1.140.826Severe incidental finding0.230.019Confirmed malignant disease1.170.85*n*374

Since the mortality risk of patients with severe aortic valve stenosis is significantly elevated,^[@JEV055C5]^ treatment should not be delayed. As shown in *Figure [2](#JEV055F2){ref-type="fig"}*, the presence of a pmIF did not change time to treatment significantly, but it was prolonged somewhat (with IF: 91 ± 152 days, range 1--729 days; without IF: 61 ± 109 days, range 1--859 days).

Follow-up period was over a period of 2 years. Two participants were lost to follow-up (one with severe, one with non-severe pmIF). If an individual\'s estimated survival was over 1 year and the heart team proposed invasive treatment, 2-year survival of these patients was around 75% and independent from the presence of an pmIF regardless of whether these findings were classified as non-severe (*P* = 0.923) or severe (*P* = 0.823) (*Figure [3](#JEV055F3){ref-type="fig"}*). Figure 3Kaplan--Meier survival curves for patients without pmIF, with severe or non-severe pmIF receiving invasive treatment (TAVR or SAVR). *P*-values for comparison of the survival distributions between groups were calculated with the log-rank test.

Discussion {#s4}
==========

Elderly patients with severe aortic valve stenosis are increasingly being treated with TAVR.^[@JEV055C17]^ Since pre-procedural planning for this requires a whole-body CT,^[@JEV055C7]^ clinicians are more and more faced with equivocal pmIF. Essentially, this corresponds to an unscheduled screening for cancers in a cohort of patients with a high prevalence for pathologies and with all known medical-economic consequences.

In 374 patients with an average age of 80 years screened for TAVR, we found a prevalence of 18.7% for pmIF suspicious for malignant diseases. This prevalence corresponds broadly to previously published findings^[@JEV055C18]^ such as Gufler *et al.*^[@JEV055C19]^ who found 23.7% significant extravascular and 3.8% highly suspicious malignant findings in patients planned for TAVR and an average age of 82 years. Since the contrast was focused on arterial phase, incidence of pmIF could be even underestimated. Similarly, performing a cardiac CT leads to confirmation of previously unknown malignancies in 0.7%, assessed by a meta-analysis,^[@JEV055C20]^ and of overall IF (not only tumour suspicious) in 13%.^[@JEV055C21]^ IF appear in around 50% of patients with CT scans for trauma and in up to 90% of patients evaluated for an aortic aneurysm.^[@JEV055C22],[@JEV055C23]^ But, clinical significance with respect to further needed diagnostic workup, change in therapy decision, or prognosis remain unclear. Particularly, the extent of radiologic findings is not obligatorily directly associated with clinical severity since the activity of the potential malignancy is unclear. Machaalany *et al.*^[@JEV055C10]^ showed direct costs for investigating IF of ∼US \$80 000 per patient in a single-centre study in Canada. However, costs are subordinate, taking into account the potential impact of IF on treatment delay, changes in decision-making, patient anxiety and possibly positive outcomes, and expense of TAVR or SAVR.

Patients with severe aortic valve stenosis are typically highly symptomatic, demonstrated by an average NYHA score of 2.6 in our cohort. This results in a mandatory and timely need for treatment, otherwise associated with high mortality.^[@JEV055C5]^ Nevertheless, since IF could represent a potential malignancy, clinicians have to interpret the radiologic finding. In our study, ∼40% of the pmIF were judged 'severe', but only 21% were finally confirmed as cancer. This indicates a gap between the radiologic finding and clinical significance. Moreover, the 'non-severe' pmIFs such as pulmonary nodes, conspicuous lymph nodes, or organ augmentation (e.g. prostate) are likely to be benign, and their clinical significance seems to be rather low,^[@JEV055C24],[@JEV055C25]^ but do generate uncertainty both to patients and physicians.^[@JEV055C26]^

As can be expected, some 'severe' findings limit life expectancy and thus argue against invasive treatment. Accordingly, patients with a 'severe' pmIF were less likely to be scheduled for SAVR or TAVR. However, half of the patients (53%) received some type of aortic valve intervention. The interdisciplinary decision for treatment was made according to the guidelines for TAVR, which recommend the procedure only in patients with an estimated survival of \>1 year.^[@JEV055C7]^ We recently published an analysis of the decision-making process in our centre and could see appropriate decisions by the heart team, since survival was around 75% in patients treated either with TAVR or SAVR.^[@JEV055C15]^ We may draw two conclusions from this: first, decision-making requires an interdisciplinary heart team and in cases of pmIF a distinct consultation of a radiology and oncology specialist; secondly, the decision to intervene (SAVR or TAVR) can be made, as our data suggest, with no differences in outcome for patients regardless of 'severe' or 'non-severe' pmIF.

Time to treatment is especially critical in patients with high-grade aortic valve stenosis and in our study pmIF prolonged time to treatment, although overall there were no differences with or without IF.

Remarkably, the appearance of a pmIF did not influence overall mortality, even if it was judged as severe. At first glance, this appears counterintuitive but may be explained by the fact that the proportion of patients invasively treated decreased with the incidence of pmIF, if cancer was confirmed and/or the pmIF was defined as severe. Accordingly, the 75% survival of patients receiving TAVR or SAVR may be seen as the result of a successful treatment selection process and therefore confirms that the interdisciplinary heart team approach is crucial for optimal treatment of patients with aortic valve stenosis.

Limitations {#s5}
===========

There are some important limitations. First, the study is a single-centre study with relatively small number of participants with heterogeneous co-morbidities and the cause of death is not known. Furthermore, we have no information about new diagnosed cancer in patients without pmIF. Thus, it is not possible to calculate a relative risk of pmIF vs. no pmIF. The results are limited by not addressing a potential specific treatment of the pmIF and the sample size of patients assigned to drug therapy only is small and does not allow mortality analysis. Thus, patients with severe pmIF, who have a life expectation under 1 year and were not treated with TAVR or SAVR according to the decision by the heart team, are not included in the survival analysis. Thus, it could also be speculated that patients would even be better able to eventually undergo cancer treatment if AVR was performed. The decision-making process of the heart team to intervene was investigated only by the final decision, but criterions to the individual patient could not be respected.

Conclusion {#s6}
==========

We conclude that aortic valve stenosis can be treated with TAVR and SAVR as long as the patient\'s estimated survival exceeds 1 year and the interdisciplinary heart team approach is efficient and beneficial. A more holistic approach to health care for all should result in better outcomes and economic savings and so the next vital step will be to evaluate the impact of early detection of malignancies and confirm benefits to the patient and society.

Translational perspective {#s7}
=========================

Elderly patients with severe aortic valve stenosis, either inoperable or at high operative risk, are increasingly treated with TAVR. Pre-procedural planning involves a body CT, and consequently, clinicians will be faced with more pmIF in the future. In our study, we found IF suspicious for malignancies in 18.7% of all patients. However, these did not significantly affect therapeutic decision or time to treatment, but severe findings were less likely assigned to invasive treatment. Two-year survival of patients, treated accordingly by TAVR or SAVR to a heart team decision was around 75% and independent of a pmIF. We conclude that aortic valve stenosis can be treated with TAVR and SAVR as long as the patient\'s estimated survival exceeds 1 year and the interdisciplinary heart team approach is efficient and beneficial.
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[^1]: Data are presented as mean ± SD or percentage/group; *P*-values were calculated by the Students *t*-test.

[^2]: Incidental diagnosis of relapse or progressive of a known malignant disease are included to the regions and are stated additionally in the last line.
